We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Rises But Trails Market: What Investors Should Know
Read MoreHide Full Article
Hologic (HOLX - Free Report) ended the recent trading session at $76.35, demonstrating a +0.58% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.63%. Elsewhere, the Dow saw an upswing of 0.2%, while the tech-heavy Nasdaq appreciated by 0.82%.
The medical device maker's stock has climbed by 2.87% in the past month, exceeding the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.
The upcoming earnings release of Hologic will be of great interest to investors. On that day, Hologic is projected to report earnings of $0.98 per share, which would represent a year-over-year decline of 7.55%. Meanwhile, our latest consensus estimate is calling for revenue of $1 billion, down 2.49% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.02 per share and revenue of $4.02 billion. These totals would mark changes of +1.52% and -0.19%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.15% lower within the past month. Hologic currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Hologic is currently trading at a Forward P/E ratio of 18.9. This valuation marks a discount compared to its industry's average Forward P/E of 27.51.
Also, we should mention that HOLX has a PEG ratio of 2.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Instruments industry had an average PEG ratio of 2.24 as trading concluded yesterday.
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 54, finds itself in the top 22% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Rises But Trails Market: What Investors Should Know
Hologic (HOLX - Free Report) ended the recent trading session at $76.35, demonstrating a +0.58% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.63%. Elsewhere, the Dow saw an upswing of 0.2%, while the tech-heavy Nasdaq appreciated by 0.82%.
The medical device maker's stock has climbed by 2.87% in the past month, exceeding the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.
The upcoming earnings release of Hologic will be of great interest to investors. On that day, Hologic is projected to report earnings of $0.98 per share, which would represent a year-over-year decline of 7.55%. Meanwhile, our latest consensus estimate is calling for revenue of $1 billion, down 2.49% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.02 per share and revenue of $4.02 billion. These totals would mark changes of +1.52% and -0.19%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.15% lower within the past month. Hologic currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Hologic is currently trading at a Forward P/E ratio of 18.9. This valuation marks a discount compared to its industry's average Forward P/E of 27.51.
Also, we should mention that HOLX has a PEG ratio of 2.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Instruments industry had an average PEG ratio of 2.24 as trading concluded yesterday.
The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 54, finds itself in the top 22% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.